Blood Proteins Patents (Class 435/69.6)
-
Publication number: 20150037334Abstract: The present invention relates to a binding molecule comprising at least three domains comprised in at least one polypeptide chain, wherein the first binding domain is a binding domain which is capable of binding to a cell surface molecule on a target cell, the second binding domain is a binding domain which is capable of binding to the T cell CD3 receptor complex, and the third domain is a binding domain which is capable of binding to serum albumin, wherein said third domain is positioned at the C-terminus of said second domain. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.Type: ApplicationFiled: March 1, 2013Publication date: February 5, 2015Inventors: Peter Kufer, Tobias Raum, Ralf Lutterbuese, Patrick Hoffmann, Markus Muenz, Johannes Brozy, Majk Kvesic
-
Publication number: 20150038401Abstract: The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragm assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.Type: ApplicationFiled: August 5, 2014Publication date: February 5, 2015Applicant: SYNTAXIN LIMITEDInventors: Andreas Rummel, Tanja Weil, Aleksandrs Gutcaits
-
Publication number: 20150040252Abstract: The invention relates to isolation of novel ?-actin and ribosomal protein S21 (rpS21) promoters and uses thereof. In particular, this invention features nucleotide sequences for rodent ?-actin promoters including, hamster, rat, and mouse, and hamster rpS21 promoter.Type: ApplicationFiled: August 1, 2014Publication date: February 5, 2015Applicant: GENZYME CORPORATIONInventors: Scott D. ESTES, Weiqun ZHANG
-
Publication number: 20150037841Abstract: The present invention relates to a method for increased production of a secreted, recombinant protein product through the introduction of molecular chaperones in a mammalian host cell. The present invention also relates to a mammalian host cell with enhanced expression of a secreted recombinant protein product by coexpressing at least one chaperone protein.Type: ApplicationFiled: June 6, 2014Publication date: February 5, 2015Inventors: Sham-Yuen Chan, Hsinyi Yvette Tang, Yiwen Tao, Yongjian Wu, Ruth Kelly
-
Publication number: 20150037323Abstract: The present invention refers to monoclonal humanized antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.Type: ApplicationFiled: July 15, 2014Publication date: February 5, 2015Applicant: U3 PHARMA GMBHInventors: Peter WIRTZ, Jens RUHE, Takeshi TAKIZAWA, Tomoko TAKAYAMA
-
Publication number: 20150037349Abstract: The present invention relates to polypeptides comprising one or more antibody single domains, or antigen-binding fragments thereof, directed against Tumor Necrosis Factor-alpha, in particular, two light chain variable domains in dimeric form, where the dimer has high solubility. It also relates to methods of using anti-Tumor Necrosis Factor-alpha polypeptides in treating inflammatory disorders, including rheumatoid arthritis. Compositions and methods for enhancing therapeutic potential of anti-Tumor Necrosis Factor-alpha polypeptides are provided, including linking the polypeptide to an albumin-binding domain and/or de-immunizing the polypeptide, to provide therapeutic agents with good solubility, enhanced serum half-life, and/or reduced immunogenicity, while substantially maintaining the specific binding properties of the anti-Tumor Necrosis Factor-alpha polypeptides.Type: ApplicationFiled: September 19, 2012Publication date: February 5, 2015Inventors: Frederico Nuno Castanheira Aires da Silva, Sofia Volker Côrte-Real, Rui Pedro da Silva Albuquerque e Freitas, Sara Ferreira Llorente Grancho Lourenço
-
Publication number: 20150037328Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.Type: ApplicationFiled: August 1, 2014Publication date: February 5, 2015Inventors: Shu-Hui LIU, Flavia Mercer PERNASETTI, Wei-Hsien HO
-
Publication number: 20150038421Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.Type: ApplicationFiled: June 27, 2014Publication date: February 5, 2015Inventors: Volker SCHELLENBERGER, Pei-Yun Chang, Fatbardha Varfaj, John Kulman, Tongyao Liu, Garabet G. Toby, Haiyan Jiang, Robert Peters, Deping Wang, Baisong Mei, Joshua Silverman, Chia-Wei Wang, Benjamin Spink, Nathan Geething
-
Patent number: 8945571Abstract: The present invention relates to immunoconjugates. In particular embodiments, the present invention relates to immunoconjugates comprising at least one single-chain effector moiety and two or more antigen binding moieties. In addition, the present invention relates to nucleic acid molecules encoding such immunoconjugates, vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.Type: GrantFiled: August 17, 2010Date of Patent: February 3, 2015Assignee: Roche GlyeArt AGInventors: Ekkehard Mössner, Ralf Jörg Hosse, Pablo Umaña, Michela Silacci-Melkko
-
Patent number: 8945867Abstract: The present invention relates to a process for producing a desired polypeptide using rat cells. Specifically, the present invention relates to a process for producing the polypeptide which comprises culturing rat cells such as YB2/3HL.P2.G11.16Ag.20 (hereinafter referred to as YB2/0), preferably rat cells to which a recombinant DNA comprising DNA encoding a desired polypeptide such as an immunologically functional molecule is introduced, in a medium which does not contain serum (hereinafter referred to as a serum-free medium). Among the desired polypeptides obtained by the process of the present invention, an antibody obtained by using a transformant of YB2/0 has a high antibody-dependent cell-mediated cytotoxic activity (hereinafter sometimes referred to as ADCC activity) and is useful as a pharmaceutical agent.Type: GrantFiled: February 2, 2009Date of Patent: February 3, 2015Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Tatsuya Ogawa, Yoshinobu Konno, Naohisa Akashi, Hiroshi Takasugi, Seiji Sugimoto, Keiichi Yano
-
Patent number: 8945857Abstract: The invention provides methods for isolating cells, particularly antibody-secreting cells that have a high likelihood of secreting antibodies specific for a desired antigen for the purpose of making monoclonal antibodies.Type: GrantFiled: June 30, 2006Date of Patent: February 3, 2015Inventor: John Schrader
-
Publication number: 20150030598Abstract: The present invention relates to tri- or tetraspecific antibodies, their manufacture and use.Type: ApplicationFiled: June 25, 2014Publication date: January 29, 2015Inventors: Rebecca CROASDALE, Christian KLEIN, Wolfgang SCHAEFER, Juergen Michael SCHANZER
-
Publication number: 20150030606Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.Type: ApplicationFiled: October 7, 2014Publication date: January 29, 2015Inventors: Ravindra Kumar, Asya Grinberg, Monique Davies, Diana Martik, Janja Cosic, Rachel Kent, David Buckler
-
Publication number: 20150031081Abstract: Described herein are methods and materials for reducing degradation of recombinant proteins in fungal cells such as Yarrowia.Type: ApplicationFiled: December 28, 2012Publication date: January 29, 2015Inventors: Wouter Vervecken, Stefan Ryckaert
-
Publication number: 20150031618Abstract: The present disclosure relates to a collection of novel muteins derived from human ?1m (or a1m) polypeptide or a functional homologue thereof. The disclosure further refers to a ?1m mutein capable of specifically binding to one or more targets other than a target to which wild-type ?1m binds. The disclosure also relates to a method for producing such collection of muteins and a method for isolating a mutein capable of binding one or more such non-natural targets of wild-type ?1m polypeptide. These aspects are made possible due to, e.g, the structural elucidation of ?1m disclosed herein by the present inventors, an appreciation of ligand-binding sights thereof and, hence, an understanding of which amino acid positions are most suitable for mutagenesis for re-engineering specificity and affinity for any given target while maintaining the secondary and/or tertiary structure of ?1m.Type: ApplicationFiled: January 31, 2013Publication date: January 29, 2015Inventors: Arne Skerra, Winfried Meining, Evelyn Eggenstein
-
Publication number: 20150030592Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.Type: ApplicationFiled: August 12, 2014Publication date: January 29, 2015Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
-
Publication number: 20150030596Abstract: A bispecific chimeric protein including a designed ankyrin repeat protein (DARPin), and an IgG antibody, an scFv-Fc antibody fragment, or a combination thereof, linked to the DARPin; a method for treating or preventing cancer using the same; and related methods and compositions.Type: ApplicationFiled: July 28, 2014Publication date: January 29, 2015Inventors: Kwang Ho CHEONG, Young Jun Koh, Min-Kyung Kim, Powei Lin, Seung Hyun Lee, Jung Wook Lee, Mi Young Cho, Jae Woong Hwang
-
Publication number: 20150031566Abstract: The invention demonstrates an improved choice of biotinylation peptide to be used in a combination or fusion with an MHC molecule for immobilizing or multimerising such MHC molecules for a variety of purposes.Type: ApplicationFiled: July 24, 2014Publication date: January 29, 2015Inventors: Catherine Elizabeth NAPPER, Nikolai Franz Gregor SCHWABE
-
Patent number: 8940276Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: December 21, 2009Date of Patent: January 27, 2015Assignees: Biogen Idec International Neuroscience GmbH, University of ZurichInventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
-
Patent number: 8940710Abstract: The present invention provides an anti-CD81 antibody usable as a pharmaceutical product for human. Specifically, the present invention provides an anti-human CD81 antibody capable of binding to a peptide region consisting of the amino acid sequence of the amino acid numbers 80 to 175 in the amino acid sequence shown in SEQ ID NO:22.Type: GrantFiled: March 15, 2013Date of Patent: January 27, 2015Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Takamasa Watanabe, Tadahiko Yoshima, Mikael Mattsson, Anna Sarnefalt, Takuya Hasezaki
-
Publication number: 20150023958Abstract: A fusion polypeptide capable of binding simultaneously to angiopoietin 2, VEGF-C and VEGF-D; or capable of binding simultaneously to VEGF-C and VEGF-D, and methods for the preparation and use thereof.Type: ApplicationFiled: July 21, 2014Publication date: January 22, 2015Inventors: Kwang Hoon LEE, Hyung-Chan Kim, Sang Yeul Han, Seok Kyun Kim, Kyung Eun Kim
-
Publication number: 20150025228Abstract: Disclosed is an IgG Fc fragment useful as a drug carrier. A recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment are disclosed. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.Type: ApplicationFiled: July 9, 2014Publication date: January 22, 2015Applicant: HANMI SCIENCE CO., LTD.Inventors: Sung Youb JUNG, Jin Sun Kim, Geun Hee Yang, Se Chang Kwon, Gwan Sun Lee
-
Publication number: 20150024433Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.Type: ApplicationFiled: July 24, 2014Publication date: January 22, 2015Applicant: NEOTOPE BIOSCIENCES LIMITEDInventors: Jose Saldanha, Tarlochan S. Nijjar
-
Publication number: 20150024432Abstract: The invention provides methods for identifying immunobinders, such as scFv antibodies, capable of specifically binding to cell surface antigens, and compositions identified according to said methods.Type: ApplicationFiled: May 8, 2014Publication date: January 22, 2015Applicant: ESBATech, an Alcon Biomedical Research Unit LLCInventors: David Urech, Valerie Hulmann-Cottier
-
Publication number: 20150024434Abstract: Herein is reported a method for a multiplex one tube real-time reverse-transcriptase gene-specific polymerase chain reaction for the amplification and quantification of cognate IgG heavy and light chains encoding nucleic acids (human IgG isotype) from a single cell.Type: ApplicationFiled: September 20, 2012Publication date: January 22, 2015Inventors: Hans-Willi Krell, Alexander Lifke, Valeria Lifke, Kairat Madin, Christian Weilke
-
Publication number: 20150023979Abstract: The invention discloses a method for preparing Human Papilloma Virus protein E7 antigen (HPV E7 antigen) comprising the following steps: —providing a purified preparation of HPV protein E7; —phosphorylating the HPV protein E7 in the preparation; —purifying the phosphorylated E7 protein with an anion exchange chromatography, wherein the phosphorylated E7 protein is separated from the non-phosphorylated E7 protein by a step wherein the non-phosphorylated E7 protein stays bound to an anion exchanger during the anion exchange chromatography whereas the phosphorylated E7 protein is obtained in the eluate of the anion exchange chromatography, thereby—obtaining a purified preparation of a phosphorylated HPV protein E7 antigen. The invention further discloses antibodies specific to this antigen, a kit and method for using such antibodies in clinical diagnostics and methods for generation of such antibodies.Type: ApplicationFiled: September 6, 2012Publication date: January 22, 2015Applicant: VALDOSPAN GMBHInventor: Christian Kuhne
-
Publication number: 20150023967Abstract: The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster3 of BCMA, and the second binding domain is capable of binding to the Tcell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.Type: ApplicationFiled: November 15, 2012Publication date: January 22, 2015Inventors: Peter Kufer, Tobias Raum, Patrick Hoffmann, Roman Kischel, Ralf Lutterbuese, Doris Rau, Paul Adam, Eric Borges, Barbara Hebeis, Susanne Hipp
-
Publication number: 20150023978Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.Type: ApplicationFiled: January 17, 2014Publication date: January 22, 2015Applicants: Baxter International Inc., Dyax Corp., Baxter Healthcare SAInventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
-
Publication number: 20150023999Abstract: The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.Type: ApplicationFiled: November 29, 2012Publication date: January 22, 2015Inventors: Simon Urwyler, Markus Haake, Michael Rodolf
-
Publication number: 20150025227Abstract: Disclosed is an IgG Fc fragment useful as a drug carrier. A recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment are disclosed. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.Type: ApplicationFiled: July 9, 2014Publication date: January 22, 2015Applicant: HANMI SCIENCE CO., LTD.Inventors: Sung Youb JUNG, Jin Sun Kim, Geun Hee Yang, Se Wang Kwon, Gwan Sun Lee
-
Publication number: 20150018532Abstract: The invention relates to antibodies to Aspergillus species and to methods of producing those antibodies. The invention also relates to the use of such antibodies in identifying the presence of the Aspergillus species and to methods of treating an infection with the Aspergillus species.Type: ApplicationFiled: June 6, 2014Publication date: January 15, 2015Applicant: UNIVERSITY OF EXETERInventor: Christopher THORNTON
-
Publication number: 20150017171Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to polypeptide antagonists of PLVAP proteins, including humanized and chimeric antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising such polypeptide antagonists.Type: ApplicationFiled: July 21, 2014Publication date: January 15, 2015Inventors: Kuo-Jang Kao, Andrew T. Huang
-
Publication number: 20150017685Abstract: The present invention relates to processes for the production of peptides, and the peptides produced accordingly. Peptides produced according to the invention may be produced more efficiently than peptides produced according to prior art processes. The production process of the invention may lead to advantages in yield, purity, and/or price. Methods of marketing peptides are also disclosed.Type: ApplicationFiled: July 8, 2014Publication date: January 15, 2015Inventors: Michael H. B. Stowell, Jonathan Caruthers, Travis Nemkov, Brian Hiester, Leslie Boux, Mikhail Plam
-
Publication number: 20150017686Abstract: Disclosed are methods for reducing detectable mannosylation of N-linked and O-linked oligosaccharides in lower eukaryote host cells. In particular, recombinant lower eukaryote host cells are provided in which expression of the GDP-mannose transporter encoded by the Vanadate Resistant Glycosylation 4 (VRG4) gene has been disrupted. In general, the VRG4 gene is essential for cell viability; however, the present invention provides host cells that are viable when expression of the VRG4 gene therein has been disrupted. The host cells are capable of producing proteins or glycoproteins that have reduced or no detectable ?-linked mannose, ?-linked mannose or phosphomannose containing N- and/or O-glycans.Type: ApplicationFiled: February 13, 2013Publication date: January 15, 2015Inventor: Stephen R. Hamilton
-
Publication number: 20150017154Abstract: A method of preparing an antibody suitable for use in a canine is provided. Also provided are caninised antibodies which specifically bind to canine neuronal growth factor (NGF) and neutralise the ability of canine NGF to bind to the p75 or TrkA canine NGF receptor. The invention extends to nucleic acids encoding same and to methods of treating pain and arthritis in a canine using said antibodies and/or nucleic acids.Type: ApplicationFiled: May 8, 2012Publication date: January 15, 2015Inventor: David Gearing
-
Publication number: 20150017095Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: July 9, 2014Publication date: January 15, 2015Inventors: Tariq Ghayur, Jijie Gu, Peter Isakson
-
Patent number: 8932830Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: November 2, 2012Date of Patent: January 13, 2015Assignee: Biogen Idec Hemophilia, Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, James McGivney, Susan C. Low
-
Patent number: 8933034Abstract: Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first polypeptide; and a second moiety of at least 5 amino acids, wherein the second moiety is derived from a second polypeptide; wherein the first polypeptide is a neuregulin and the chimeric neuregulin exhibits an enhanced binding affinity to integrin, Erb 3, or Erb 4 comparing to that of the first neuregulin.Type: GrantFiled: April 18, 2013Date of Patent: January 13, 2015Assignee: Brain-Gen BiotechInventor: Byron D. Ford
-
Patent number: 8932592Abstract: The present invention features compositions and methods related to humanized antibodies and FKN-binding fragments thereof that bind fractalkine.Type: GrantFiled: October 28, 2010Date of Patent: January 13, 2015Assignee: Eisai R&D Management Co., Ltd.Inventors: Miyuki Nishimura, Yoshimasa Sakamoto, Tetsu Kawano, Toshio Imai
-
Patent number: 8932829Abstract: Disclosed are pharmaceutical and synergistic compositions comprising human recombinant alpha-fetoprotein expressed in eucaryotic cells for preparation of therapeutic agents for use in oncology, immunotherapy, stem cell therapy and cosmetology and also for the diagnosis of cancer and embryonic pathologies.Type: GrantFiled: October 22, 2010Date of Patent: January 13, 2015Inventors: Elena Dudich, Lydia Semenkova, Igor Dudich, Eduard Tatulov
-
Publication number: 20150010546Abstract: The present invention relates to biological materials against HGF and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the biological materials of the present invention inhibit binding of HGF to its receptor c-Met.Type: ApplicationFiled: January 16, 2013Publication date: January 8, 2015Inventors: Joost Alexander Kolkman, Hilde Adi Pierrette Revets, Jo Vercammen, Augustinus Antonius Maria Silvester van Dongen
-
Publication number: 20150010946Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: ApplicationFiled: June 5, 2014Publication date: January 8, 2015Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Jane A. Gross, Angela K. Hammond
-
Publication number: 20150010543Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.Type: ApplicationFiled: July 8, 2014Publication date: January 8, 2015Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
-
Publication number: 20150011431Abstract: The present disclosure provides humanized antibodies, including antibodies comprising an ultralong CDR3 (e.g. bovine) and uses thereof.Type: ApplicationFiled: January 9, 2013Publication date: January 8, 2015Inventors: Vaughn Smider, Omar A. Bazirgan, Hongyuan Helen Mao
-
Publication number: 20150010560Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.Type: ApplicationFiled: June 13, 2014Publication date: January 8, 2015Inventors: Cen XU, Agnes Eva HAMBURGER
-
Publication number: 20150010567Abstract: The present invention relates to a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor.Type: ApplicationFiled: January 24, 2013Publication date: January 8, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Carole Bourquin, Raffaella Castoldi, Stefan Endres, Christian Klein, Sebastian Kobold, Gerhard Niederfellner, Claudio Sustmann
-
Publication number: 20150010584Abstract: The present invention is related to compositions and methods to stimulate the immune system. For example, antigen-specific antibodies may be produced by stimulating B cell populations with specific antigenic compounds, such as an adjuvant comprising a macromolecule capable of activating a Toll-Like receptor (TLR). For example, a BCR adapter IgM (BCRAM) is described to exemplify delivery of autoantigens to polyclonal B cell populations resulting in immunoactivation by TLR activation. Alternatively, a compound is described that inhibits TLR activation.Type: ApplicationFiled: June 26, 2014Publication date: January 8, 2015Inventors: Ann Marshak-Rothstein, Krishna Moody
-
Publication number: 20150010574Abstract: Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.Type: ApplicationFiled: June 13, 2014Publication date: January 8, 2015Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Paul ADAM, Eric BORGES
-
Publication number: 20150010539Abstract: The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.Type: ApplicationFiled: March 14, 2014Publication date: January 8, 2015Applicant: AbbVie Biotherapeutics Inc.Inventors: YOSHIKO AKAMATSU, FIONA A. HARDING, PAUL R. HINTON, MENGLI XIONG, OLIVIA JENNIFER RAZO, SHIMING YE
-
Publication number: 20150010566Abstract: The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for multiple influenza A virus subtypes. The invention further relates to the use of such antibodies for diagnosis of an influenza A virus infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of an influenza A virus infection.Type: ApplicationFiled: December 3, 2012Publication date: January 8, 2015Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Arjen Quirinus Bakker